The Polymorphism −308G/A of Tumor Necrosis Factor-α Gene Modulates the Effect of Immunosuppressive Treatment in First Kidney Transplant Subjects Who Suffer an Acute Rejection

Table 2

Univariate analysis for acute rejection in the discovery cohort ().

	Acute rejection (%)	OR (95% CI)	value
Recipient age			0.04
<60 years	43 (22.6%)	2.04 (1.02 to 4.17)
≥60	12 (12.5%)	1
Recipient sex			0.17
Male	41 (21.5%)	1.59 (0.81 to 3.03)
Female	14 (14.7%)	1
Donor age			0.05
<60 years	54 (20.6%)	5.88 (0.81 to 50.0)
≥60	1 (4.2%)	1
Donor sex			0.22
Male	44 (21.1%)	1.72 (0.83 to 3.70)
Female	11 (14.5%)	1
Time on dialysis			0.64
<15 months	24 (18.0%)	1
≥15 months	31 (20.3%)	1.15 (0.64 to 2.09)
Donor type			0.47
Brain death	19 (17.1%)	1
Circulatory death	36 (20.6%)	1.25 (0.68 to 2.32)
Delayed graft function			0.45
Yes	30 (21.0%)	1.25 (0.70 to 2.26)
No	25 (17.5%)	1
TNF-  −308 polymorphism			0.003
GG	38 (16.0%)	1
GA/AA	17 (34.6%)	2.78 (1.40 to 5.51)
Immunosuppressive treatment			0.003
Thymoglobulin + FK + MMF + P	8 (8.2%)	1
IL2R + FK + MMF + P	32 (25.2%)	3.74 (1.63 to 8.57)
Other (belatacept, SRL)	15 (24.2%)	3.55 (1.40 to 8.98)
HLA mismatch			0.75
<3	4 (22.2%)	1.20 (1.38 to 3.85)
≥3	51 (19.1%)	1
HLA-DR mismatch			0.22
≤1	34 (21.9%)	1
2	21 (16.2%)	0.69 (0.38 to 1.25)
HLA-A mismatch			0.86
≤1	28 (19.7%)	1
2	27 (18.9%)	0.95 (0.52 to 1.71)
HLA-B mismatch			0.56
≤1	22 (17.7%)	1
2	33 (20.5%)	1.20 (0.66 to 2.18)

FK: tacrolimus; MMF: mycophenolate; P: prednisone; IL2R: interleukin- (IL-) 2 receptor antagonist; SRL: sirolimus.